Synairgen plc

Equities

SNG

GB00B0381Z20

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:20 2024-04-26 am EDT			5-day change	1st Jan Change
6.49 ^GBX	-1.52%		-3.85%	+8.62%

2023	FTSE 100 Finishes Slightly Lower After Steady Session	DJ
2023	Synairgen names Phytome's Joseph Colliver as CFO	AN

Synairgen promotes Marcin Mankowski to chief medical officer

October 03, 2023 at 05:02 am EDT

(Alliance News) - Synairgen PLC on Tuesday promoted Marcin Mankowski to chief medical officer, effective immediately.

Synairgen is a Southampton, England-based drug discovery and biotechnology firm developing SNG001 antiviral treatment for lung infections. Shares in Synairgen were down 6.2% to 7.45 pence each in London on Tuesday morning.

Mankowski has been at Synairgen since 2018. He has held the roles of acting CMO and a clinical trials consultant whilst being at the company.

Synairgen added that Mankowski is a pharmaceutical physician and drug developer with more than 27 years of pharmaceutical industry experience.

Prior to joining Synairgen, Mankowski was co-founder and chief executive officer at tranScrip Ltd. Synairgen describes tranScrip as a "leading contract drug development business."

CEO Richard Marsden said: "Since 2018, he has been supporting and guiding us on our clinical trials and his appointment today underlines his belief in our drug. Marcin's in-depth knowledge of the Company and SNG001 as well as his strong track record in leading the strategy, design and implementation of global clinical development programmes, will be invaluable to us as we prepare to enter further clinical trials of SNG001."

By Sophie Rose, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Latest news about Synairgen plc

FTSE 100 Finishes Slightly Lower After Steady Session	23-10-11	DJ
Synairgen names Phytome's Joseph Colliver as CFO	23-10-11	AN
Biotech Company Synairgen Names New CFO	23-10-11	MT
Synairgen plc Announces Executive Changes	23-10-11	CI
Synairgen plc Announces Board Changes	23-10-11	CI
Synairgen promotes Marcin Mankowski to chief medical officer	23-10-03	AN
Synairgen plc Announces Appointment of Dr. Marcin Mankowski as Chief Medical Officer	23-10-03	CI
Synairgen narrows interim loss on reduced R&D spending	23-09-21	AN
Earnings Flash (SNG.L) SYNAIRGEN Posts H1 Loss GBX-2.36	23-09-21	MT
Synairgen plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
Synairgen loss narrows; aims to develop SNG001	23-04-27	AN
Earnings Flash (SNG.L) SYNAIRGEN Reports FY22 Loss GBX-8.76	23-04-27	MT
Synairgen plc Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-27	CI
TRADING UPDATES: SulNOx raises funds; Synairgen shares trial results	22-12-23	AN
Synairgen plc Announces the Online Publication of Data from Its Phase 3 Sprinter Trial in the Peer Reviewed European Respiratory Journal Open Research	22-12-23	CI
Synairgen plc Appoints Amanda Radford FCA to the Board as an Independent Non-Executive Director and Chair of the Audit Committee	22-12-01	CI
Synairgen Unveils Promising Phase Two Trial Results for Investigational Treatment Against COVID-19	22-10-04	MT
Synairgen plc Announces Topline Data for Participants Treated with Sng001 in the Us National Institutes of Health/ Aids Clinical Trials Group-Led Activ-2 Phase 2 Adaptive Platform Trial for Covid-19	22-10-04	CI
Earnings Flash (SNG.L) SYNAIRGEN Posts H1 Loss GBX-6.16	22-09-29	MT
Synairgen plc Announces Changes to Its Board	22-09-29	CI
Synairgen plc Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-29	CI
Synairgen plc to Present 60 and 90-Day Long COVID Data from Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022	22-09-20	CI
Synairgen's SNG001 Reduces Long COVID-19 Symptoms In Follow-up Visits After Late-stage Trial	22-09-20	MT
Synairgen Announces Positive Findings from Analysis of Lung Samples from the SG015 Trial of SNG001 in Virally Infected COPD Patients	22-09-07	CI
Synairgen Surges 10% After Analysis Finds Antiviral Inhaler Accelerates Virus Removal in Lungs	22-09-07	MT

Chart Synairgen plc

Duration

Period

More charts

Company Profile

Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company; Synairgen Inc. and Synairgen Research (Ireland) Limited. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.

Sector

Biotechnology & Medical Research

Calendar

2024-09-25 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0649 GBP

Average target price

0.4 GBP

Spread / Average Target

+516.33%

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
SYNAIRGEN PLC	+8.62%	16.28M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research